Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-56.7	-12.41	-3.42	-9.52	-0.29
Depreciation & Amortization	5.95	7.16	7	7.58	7.62
Stock-Based Compensation	1.86	4.34	5	4.41	4.17
Other Adjustments	49.96	2.28	0.85	-4.03	-0.05
Change in Receivables	-0.93	0.97	0.81	4.78	-4.29
Changes in Inventories	2.95	-0.06	1.52	0.25	-5.86
Changes in Unearned Revenue	-0.16	-0.7	1.14	-0.9	0.51
Changes in Other Operating Activities	3.82	-0.14	1.13	-1.42	-0.54
Operating Cash Flow	6.73	1.44	14.03	1.15	1.26
Operating Cash Flow Growth	367.29%	-89.73%	1117.71%	-8.72%	-86.48%
Capital Expenditures	-1.26	-2.64	-1.79	-1.59	-1.2
Purchases of Intangible Assets	-0.61	-0.62	-0.52	-	-0.15
Proceeds from Sale of Investments	-	1.92	-	-	-
Proceeds from Business Divestments	-	-	0.51	-	-
Investing Cash Flow	-1.86	-1.34	-1.8	-1.59	-1.35
Long-Term Debt Issued	40	8.8	4.5	7.8	4.25
Long-Term Debt Repaid	-37.35	-8.57	-15.04	-9.59	-4.2
Net Long-Term Debt Issued (Repaid)	2.65	0.23	-10.54	-1.79	0.05
Issuance of Common Stock	0.05	0.38	0.93	0.58	3.31
Repurchase of Common Stock	-0.16	-0.58	-2.52	-1.63	-3.51
Net Common Stock Issued (Repurchased)	-0.11	-0.2	-1.59	-1.05	-0.2
Other Financing Activities	-3.83	-0.16	-	-	-0.1
Financing Cash Flow	-1.29	-0.13	-12.13	-2.84	-0.25
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.93	-0.14	-0.32	-0.04	-0.16
Net Cash Flow	4.51	-0.18	-0.23	-3.31	-0.5
Free Cash Flow	5.47	-1.2	12.24	-0.44	0.07
Free Cash Flow Growth	-	-	-	-	-99.18%
FCF Margin	6.32%	-1.28%	10.90%	-0.39%	0.06%
Free Cash Flow Per Share	1.23	-0.28	2.89	-0.11	0.02
Levered Free Cash Flow	-42.76	-8.57	-4.96	-7.38	0.29
Unlevered Free Cash Flow	-36.78	-2.88	11.13	-3.22	2.73

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q